Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.

ABSTRACT:

Background

Erenumab is a fully human monoclonal antibody and a highly potent, first-in-class calcitonin gene-related peptide receptor inhibitor approved for migraine prevention in adults. Randomised, placebo-controlled trials show that erenumab treatment results in clinically meaningful responses, including significant reductions in monthly migraine days. Real-world evidence of the effectiveness of erenumab in patients with migraine is accruing, but gaps remain, and findings may vary according to region. We evaluated the usage patterns and effectiveness of erenumab in real-world settings in patients with migraine in the United Arab Emirates (UAE).

Methods

This retrospective, observational real-world study enrolled patients ≥ 18 years with migraine who were prescribed erenuma

SUBMITTER: Alsaadi T 

PROVIDER: S-EPMC9202108 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature